Zelluna ASA (OSTO:ULTIO) Land And Improvements : kr0.00 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Zelluna ASA Land And Improvements?

Zelluna ASA's land and improvements for the quarter that ended in Mar. 2025 was kr0.00 Mil.

Zelluna ASA Land And Improvements Historical Data

The historical data trend for Zelluna ASA's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelluna ASA Land And Improvements Chart

Zelluna ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Get a 7-Day Free Trial

Zelluna ASA Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Zelluna ASA Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Zelluna ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelluna ASA (OSTO:ULTIo) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

ZLNA:Norway 7UM0:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.zelluna.com

Zelluna ASA is a clinical-stage biotechnology company developing novel immunotherapies against cancer and the development of T-Cell Receptor Natural Killer cell therapies for the treatment of solid cancers. The company's current pipeline consists of allogeneic TCR-NK R&D programs ZI-MA4-1, ZI-KL1-1, and ZI-PR-1 targeting well validated antigens expressed across a broad range of solid tumors.

Zelluna ASA Headlines

No Headlines